Business Description
Nephros Inc
NAICS : 339112
SIC : 3841
ISIN : US6406714005
Total Employee Number:
36Description
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.15 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 1.11 | |||||
Interest Coverage | 677 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.68 | |||||
Beneish M-Score | -1.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.9 | |||||
3-Year Book Growth Rate | 20.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.95 | |||||
9-Day RSI | 57.21 | |||||
14-Day RSI | 54.92 | |||||
3-1 Month Momentum % | 17.6 | |||||
6-1 Month Momentum % | -35.53 | |||||
12-1 Month Momentum % | -11.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.55 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 1.59 | |||||
Days Inventory | 131.32 | |||||
Days Sales Outstanding | 50.82 | |||||
Days Payable | 42.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | 0.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.95 | |||||
Operating Margin % | 3.54 | |||||
Net Margin % | 4.06 | |||||
EBITDA Margin % | 4.58 | |||||
FCF Margin % | -1.84 | |||||
OCF Margin % | -1.84 | |||||
ROE % | 7.79 | |||||
ROA % | 6 | |||||
ROIC % | 10.48 | |||||
3-Year ROIIC % | -1151.48 | |||||
ROC (Joel Greenblatt) % | 14.77 | |||||
ROCE % | 6.95 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 59.17 | |||||
Forward PE Ratio | 57.25 | |||||
PE Ratio without NRI | 59.17 | |||||
PS Ratio | 2.05 | |||||
PB Ratio | 3.6 | |||||
Price-to-Tangible-Book | 4.05 | |||||
EV-to-EBIT | 47.58 | |||||
EV-to-EBITDA | 40.51 | |||||
EV-to-Revenue | 1.86 | |||||
EV-to-FCF | -101.99 | |||||
Price-to-GF-Value | 1.23 | |||||
Price-to-Median-PS-Value | 0.39 | |||||
Price-to-Graham-Number | 3.25 | |||||
| Price-to-Net-Current-Asset-Value | 4.63 | |||||
| Price-to-Net-Cash | 37 | |||||
Earnings Yield (Greenblatt) % | 2.1 | |||||
FCF Yield % | -0.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nephros Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 16.437 | ||
| EPS (TTM) (€) | 0.052 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 48.62 | ||
| 14-Day RSI | 54.92 | ||
| 14-Day ATR (€) | 0.151804 | ||
| 20-Day SMA (€) | 2.831 | ||
| 12-1 Month Momentum % | -11.98 | ||
| 52-Week Range (€) | 2.28 - 4.76 | ||
| Shares Outstanding (Mil) | 10.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nephros Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nephros Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| General meeting for 2026 | 2026-07-07 | 2.90 (+0.69%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 2.72 (+4.62%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.72 (+4.62%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 16:30 | 3.34 (-3.47%) | ||
| Annual report for 2025 | 2026-03-12 | 3.34 (-3.47%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 3.34 (-3.47%) |
Show
Entries
Nephros Inc Frequently Asked Questions
What is Nephros Inc(STU:NPJP)'s stock price today?
The current price of STU:NPJP is €2.96. The 52 week high of STU:NPJP is €4.76 and 52 week low is €2.28.
When is next earnings date of Nephros Inc(STU:NPJP)?
The next earnings date of Nephros Inc(STU:NPJP) is 2026-08-07 Est..
Does Nephros Inc(STU:NPJP) pay dividends? If so, how much?
Nephros Inc(STU:NPJP) does not pay dividend.
Articles on Nephros Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers